Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma

Histopathology

Volumn 66, Issue 3, 2015, Pages 370-379

  Ramani, Pramila ^a,b   Nash, Rachel ^a   Rogers, Chris A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aurora kinase a; Digital imaging analysis; Immunohistochemistry; Ki67; MIB 1; Neuroblastoma; Prognosis

Indexed keywords

AURORA A KINASE; KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; EVENT FREE SURVIVAL; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEWBORN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; AURORA KINASE A; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; NEUROBLASTOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84921600093     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12520     Document Type: Article

References (28)

1. Park JR, Bagatell R, London WB et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr. Blood Cancer 2013; 60; 985-993.
2. Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 2009; 27; 289-297.
3. Cotterill SJ, Pearson AD, Pritchard J et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur. J. Cancer 2000; 36; 901-908.
4. Shimada H, Ambros IM, Dehner LP et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86; 364-372.
5. Williams GH, Stoeber K. The cell cycle and cancer. J. Pathol. 2012; 226; 352-364.
6. Burgues O, Navarro S, Noguera R et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch. 2006; 449; 410-420.
7. Mejia C, Navarro S, Pellin A, Ruiz A, Castel V, Llombart-Bosch A. Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors. Oncol. Rep. 2003; 10; 243-247.
8. Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 2002; 94; 854-861.
9. Izycka-Swieszewska E, Wozniak A, Kot J et al. Prognostic significance of HER2 expression in neuroblastic tumors. Mod. Pathol. 2010; 23; 1261-1268.
10. Loddo M, Kingsbury SR, Rashid M et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br. J. Cancer 2009; 100; 959-970.
11. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br. J. Cancer 2012; 106; 1798-1806.
12. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 2008; 1786; 60-72.
13. Shang X, Burlingame SM, Okcu MF et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 2009; 8; 2461-2469.
14. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog. Clin. Biol. Res. 1994; 385; 363-369.
15. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. Prog. Clin. Biol. Res. 1988; 271; 509-524.
16. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86; 349-363.
17. Peuchmaur M, d'Amore ES, Joshi VV et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003; 98; 2274-2281.
18. Ramani P, Headford A, May MT. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 2013; 462; 203-209.
19. Gudlaugsson E, Skaland I, Janssen EA et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 2012; 61; 1134-1144.
20. Braun M, Kirsten R, Rupp NJ et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol. Histopathol. 2013; 28; 605-610.
21. Nowak M, Svensson MA, Carlsson J et al. Prognostic significance of phospho-histone H3 in prostate carcinoma. World J. Urol. 2014; 32; 703-707.
22. Korja M, Finne J, Salmi TT et al. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod. Pathol. 2005; 18; 1599-1605.
23. Neben K, Korshunov A, Benner A et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004; 64; 3103-3111.
24. Samaras V, Stamatelli A, Samaras E et al. Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features. Pathol. Res. Pract. 2009; 205; 765-773.
25. Carol H, Boehm I, Reynolds CP et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother. Pharmacol. 2011; 68; 1291-1304.
26. Maris JM, Morton CL, Gorlick R et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2010; 55; 26-34.
27. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr. 2006; 18; 634-638.
28. Otto T, Horn S, Brockmann M et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15; 67-78.